Loading...

PerCP/Cyanine5.5 anti-mouse CD45.2 Antibody PerCP/Cyanine5.5 anti-mouse CD45.2 Antibody

Pricing & Availability
Clone
104 (See other available formats)
Regulatory Status
RUO
Other Names
Ly-5.2, LCA
Isotype
Mouse (SJL) IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
104_PerCPCy5dot5_011108
C57BL/6 mouse splenocytes stained with 104 PerCP/Cyanine5.5
  • 104_PerCPCy5dot5_011108
    C57BL/6 mouse splenocytes stained with 104 PerCP/Cyanine5.5
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability Save
109827 25 µg DKK499
Check Availability


Need larger quantities of this item?
Request Bulk Quote
109828 100 µg DKK1592
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45.2 is an alloantigen of CD45, expressed by Ly5.2 bearing mouse strains (e.g., A, AKR, BALB/c, CBA/Ca, CBA/J, C3H/He, C57BL, C57BR, C57L, C58, DBA/1, DBA/2, NZB, SWR, 129). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in the mouse that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
B10.S mouse thymocytes and splenocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The 104 antibody does not react with mouse cells expressing the CD45.1 alloantigen. Additional reported applications (for the relevant formats) include: immunoprecipitation4, in vivo and in vitro blocking of B cell responses1,2, and immunohistochemical staining of acetone-fixed frozen sections3. 

Application References
  1. Yakura H, et al. 1983. J. Exp. Med. 157:1077. (Block)
  2. Yakura H, et al. 1986. J. Immunol. 136:2729. (Block)
  3. Suzuki K, et al. 2000. Immunity 13:691. (IHC)
  4. Shen FW, et al. 1986. Immunogenetics 24:146. (IP)
  5. Baldwin TA and Hogquist KA. 2007. J. Immunol. 179:837.
  6. Pascal V, et al. 2007. J. Immunol. 179:1751.
  7. Burman AC, et al. 2007. Blood 110:1064.
  8. Kincaid EZ, et al. 2007. J. Immunol. 179:3187.
  9. Phan TG, et al. 2007. Nature Immunol. 8:992.
  10. Nakano-Yokomizo T, et al. 2011. J. Exp Med. 208:1661. PubMed
  11. Wen T, et al. 2013. PNAS. 110:6067. PubMed
  12. Kohlmeier JE, et al. 2008. Immunity. 29:101. (FC) PubMed
Product Citations
  1. Lee KM, et al. 2022. Cancer Immunol Res. 10:829. PubMed
  2. Li T, et al. 2022. J Leukoc Biol. 112:845. PubMed
  3. Song S, et al. 2023. Bioact Mater. 28:358. PubMed
  4. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  5. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  6. Wang Y, et al. 2021. Cancer Res. 81:174. PubMed
  7. Nozaki K, et al. 2022. Nature. 606:960. PubMed
  8. VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed
  9. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  10. Vijver SV, et al. 2023. Front Immunol. 13:1100730. PubMed
  11. Sun Y, et al. 2023. Cell Mol Life Sci. 80:63. PubMed
  12. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  13. Li X, et al. 2022. Cell. 185:1709. PubMed
  14. Charpentier JC, et al. 2020. Nat Commun. 11:180. PubMed
  15. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  16. Emal D, et al. 2016. J Am Soc Nephrol. 10.1681/ASN.2016030255. PubMed
  17. Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed
  18. Zhang LJ, et al. 2019. Immunity. 50:121. PubMed
  19. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  20. Yu K, et al. 2021. Cell Reports. 35(12):109273. PubMed
  21. Scalzo S, et al. 2022. Int J Nanomedicine. 17:2865. PubMed
  22. Turner JS et al. 2018. Cell reports. 25(6):1395-1403 . PubMed
  23. Stewart I et al. 2018. Immunity. 49(3):477-489 . PubMed
  24. Fu B et al. 2017. Immunity. 47(6):1100-1113 . PubMed
  25. Low MSY, et al. 2019. Cell Reports. 29(9):2634-2645.e5. PubMed
  26. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  27. Rothchild AC, et al. 2020. Bio Protoc. 10:00. PubMed
  28. Isoda T et al. 2017. Cell. 171(1):103-119 . PubMed
  29. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  30. Rodriguez-Ruiz M, et al. 2016. Cancer Res . 76: 5994 - 6005. PubMed
  31. Kleinholz CL, et al. 2021. Sci Rep. 11:15071. PubMed
  32. Yang F, et al. 2020. Cancer Res. 80:3677. PubMed
  33. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  34. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  35. Stivala S, et al. 2019. J Clin Invest. 130:1596. PubMed
  36. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  37. Ramos CV, et al. 2020. Cell Reports. 32(3):107910. PubMed
  38. Tian Y, et al. 2016. J Immunol. 196: 2153 - 2166. PubMed
  39. Yap JY, et al. 2018. Immunology. 154:522. PubMed
  40. Zhang K, et al. 2014. PLoS Pathog. 10:1004385. PubMed
  41. Venturutti L, et al. 2020. Cell. 182(2):297-316.e27. PubMed
  42. Chen Z et al. 2019. Immunity. 51(5):840-855 . PubMed
  43. Hulsmans M et al. 2017. Cell. 169(3):510-522 . PubMed
  44. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  45. Xu S, et al. 2021. Immunity. . PubMed
  46. Stotesbury C, et al. 2020. J Immunol. 204:1582. PubMed
  47. Kan X, et al. 2015. Cardiovasc Res. 10.1093/cvr/cvv255. PubMed
  48. Fraccarollo D, et al. 2021. eLife. 0.416666666666667. PubMed
  49. Olson GS, et al. 2021. Cell Reports. 35(9):109195. PubMed
  50. Tian Y, et al. 2016. J Immunol. 197: 1308 - 1321. PubMed
  51. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  52. Liu C et al. 2019. Immunity. 51(2):381-397 . PubMed
  53. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  54. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  55. Giampazolias E, et al. 2021. Cell. . PubMed
  56. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  57. MacKinnon A, et al. 2011. Am J Respir Crit Care Med. 185:537. PubMed
  58. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  59. Ulland T, et al. 2016. Nat Commun. 7:13180. PubMed
  60. Wang X, et al. 2016. J Immunol. 197(12):4750-4761. PubMed
  61. Chen Z, et al. 2021. Cell. 184(5):1262-1280.e22. PubMed
  62. Forero A, et al. 2020. Immunity. 51(3):451-464. PubMed
  63. Tang W, et al. 2021. Front Cell Dev Biol. 9:728057. PubMed
  64. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  65. Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed
  66. Cao H, et al. 2020. Front Pharmacol. 11:578943. PubMed
  67. Martins R, et al. 2016. Nat Immunol. 17:1361-1372. PubMed
  68. Ikeda T, et al. 2014. PLoS One. 9:115198. PubMed
  69. Gundra UM, et al. 2017. Nat Immunol. 1.195833333. PubMed
  70. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  71. Cabal-Hierro L, et al. 2020. Nat Commun. 11:1406. PubMed
  72. Lee KM, et al. 2022. Cancer Immunol Res. 10:829. PubMed
  73. Li T, et al. 2022. J Leukoc Biol. 112:845. PubMed
  74. Song S, et al. 2023. Bioact Mater. 28:358. PubMed
  75. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  76. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  77. Wang Y, et al. 2021. Cancer Res. 81:174. PubMed
  78. Nozaki K, et al. 2022. Nature. 606:960. PubMed
  79. VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed
  80. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  81. Vijver SV, et al. 2023. Front Immunol. 13:1100730. PubMed
  82. Sun Y, et al. 2023. Cell Mol Life Sci. 80:63. PubMed
  83. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  84. Li X, et al. 2022. Cell. 185:1709. PubMed
  85. Charpentier JC, et al. 2020. Nat Commun. 11:180. PubMed
  86. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  87. Emal D, et al. 2016. J Am Soc Nephrol. 10.1681/ASN.2016030255. PubMed
  88. Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed
  89. Zhang LJ, et al. 2019. Immunity. 50:121. PubMed
  90. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  91. Yu K, et al. 2021. Cell Reports. 35(12):109273. PubMed
  92. Scalzo S, et al. 2022. Int J Nanomedicine. 17:2865. PubMed
  93. Turner JS et al. 2018. Cell reports. 25(6):1395-1403 . PubMed
  94. Stewart I et al. 2018. Immunity. 49(3):477-489 . PubMed
  95. Fu B et al. 2017. Immunity. 47(6):1100-1113 . PubMed
  96. Low MSY, et al. 2019. Cell Reports. 29(9):2634-2645.e5. PubMed
  97. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  98. Rothchild AC, et al. 2020. Bio Protoc. 10:00. PubMed
  99. Isoda T et al. 2017. Cell. 171(1):103-119 . PubMed
  100. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  101. Rodriguez-Ruiz M, et al. 2016. Cancer Res . 76: 5994 - 6005. PubMed
  102. Kleinholz CL, et al. 2021. Sci Rep. 11:15071. PubMed
  103. Yang F, et al. 2020. Cancer Res. 80:3677. PubMed
  104. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  105. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  106. Stivala S, et al. 2019. J Clin Invest. 130:1596. PubMed
  107. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  108. Ramos CV, et al. 2020. Cell Reports. 32(3):107910. PubMed
  109. Tian Y, et al. 2016. J Immunol. 196: 2153 - 2166. PubMed
  110. Yap JY, et al. 2018. Immunology. 154:522. PubMed
  111. Zhang K, et al. 2014. PLoS Pathog. 10:1004385. PubMed
  112. Venturutti L, et al. 2020. Cell. 182(2):297-316.e27. PubMed
  113. Chen Z et al. 2019. Immunity. 51(5):840-855 . PubMed
  114. Hulsmans M et al. 2017. Cell. 169(3):510-522 . PubMed
  115. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  116. Xu S, et al. 2021. Immunity. . PubMed
  117. Stotesbury C, et al. 2020. J Immunol. 204:1582. PubMed
  118. Kan X, et al. 2015. Cardiovasc Res. 10.1093/cvr/cvv255. PubMed
  119. Fraccarollo D, et al. 2021. eLife. 0.416666666666667. PubMed
  120. Olson GS, et al. 2021. Cell Reports. 35(9):109195. PubMed
  121. Tian Y, et al. 2016. J Immunol. 197: 1308 - 1321. PubMed
  122. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  123. Liu C et al. 2019. Immunity. 51(2):381-397 . PubMed
  124. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  125. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  126. Giampazolias E, et al. 2021. Cell. . PubMed
  127. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  128. MacKinnon A, et al. 2011. Am J Respir Crit Care Med. 185:537. PubMed
  129. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  130. Ulland T, et al. 2016. Nat Commun. 7:13180. PubMed
  131. Wang X, et al. 2016. J Immunol. 197(12):4750-4761. PubMed
  132. Chen Z, et al. 2021. Cell. 184(5):1262-1280.e22. PubMed
  133. Forero A, et al. 2020. Immunity. 51(3):451-464. PubMed
  134. Tang W, et al. 2021. Front Cell Dev Biol. 9:728057. PubMed
  135. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  136. Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed
  137. Cao H, et al. 2020. Front Pharmacol. 11:578943. PubMed
  138. Martins R, et al. 2016. Nat Immunol. 17:1361-1372. PubMed
  139. Ikeda T, et al. 2014. PLoS One. 9:115198. PubMed
  140. Gundra UM, et al. 2017. Nat Immunol. 1.195833333. PubMed
  141. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  142. Cabal-Hierro L, et al. 2020. Nat Commun. 11:1406. PubMed
RRID
AB_893352 (BioLegend Cat. No. 109827)
AB_893350 (BioLegend Cat. No. 109828)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets of the CD45.2 strain of mice

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules
Antigen References

1. Suzuki K, et al. 2000. Immunity 13:691.

Gene ID
19264 View all products for this Gene ID
UniProt
View information about CD45.2 on UniProt.org

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Other Formats

View All CD45.2 Reagents Request Custom Conjugation
Description Clone Applications
PE/Dazzle™ 594 anti-mouse CD45.2 104 FC
Purified anti-mouse CD45.2 (Maxpar® Ready) 104 FC,CyTOF®
Brilliant Violet 711™ anti-mouse CD45.2 104 FC
Alexa Fluor® 594 anti-mouse CD45.2 104 IHC-F,SB
APC/Fire™ 750 anti-mouse CD45.2 104 FC
TotalSeq™-A0157 anti-mouse CD45.2 104 PG
TotalSeq™-B0157 anti-mouse CD45.2 104 PG
TotalSeq™-C0157 anti-mouse CD45.2 104 PG
Brilliant Violet 750™ anti-mouse CD45.2 104 FC
Spark Blue™ 550 anti-mouse CD45.2 104 FC
Spark NIR™ 685 anti-mouse CD45.2 104 FC
Biotin anti-mouse CD45.2 104 FC
FITC anti-mouse CD45.2 104 FC
PE anti-mouse CD45.2 104 FC
Purified anti-mouse CD45.2 104 FC,Block,IHC-F,IP
APC anti-mouse CD45.2 104 FC
Alexa Fluor® 488 anti-mouse CD45.2 104 FC
Alexa Fluor® 647 anti-mouse CD45.2 104 FC
Pacific Blue™ anti-mouse CD45.2 104 FC
Alexa Fluor® 700 anti-mouse CD45.2 104 FC
APC/Cyanine7 anti-mouse CD45.2 104 FC
PerCP/Cyanine5.5 anti-mouse CD45.2 104 FC
PerCP anti-mouse CD45.2 104 FC
PE/Cyanine7 anti-mouse CD45.2 104 FC
Brilliant Violet 421™ anti-mouse CD45.2 104 FC
Brilliant Violet 570™ anti-mouse CD45.2 104 FC
Brilliant Violet 510™ anti-mouse CD45.2 104 FC
Brilliant Violet 650™ anti-mouse CD45.2 104 FC
Brilliant Violet 785™ anti-mouse CD45.2 104 FC
Brilliant Violet 605™ anti-mouse CD45.2 104 FC
Spark UV™ 387 anti-mouse CD45.2 104 FC
Spark Blue™ 574 anti-mouse CD45.2 (Flexi-Fluor™) 104 FC
Spark Red™ 718 anti-mouse CD45.2 (Flexi-Fluor™) 104 FC
Spark YG™ 581 anti-mouse CD45.2 (Flexi-Fluor™) 104 FC
Spark YG™ 593 anti-mouse CD45.2 (Flexi-Fluor™) Antibody 104 FC
Go To Top Version: 2    Revision Date: 09/18/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
104 (See other available formats)
Regulatory Status
RUO
Other Names
Ly-5.2, LCA
Isotype
Mouse (SJL) IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
104_PerCPCy5dot5_011108
C57BL/6 mouse splenocytes stained with 104 PerCP/Cyanine5.5
  • 104_PerCPCy5dot5_011108
    C57BL/6 mouse splenocytes stained with 104 PerCP/Cyanine5.5
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability Save
109827 25 µg DKK499
Check Availability


Need larger quantities of this item?
Request Bulk Quote
109828 100 µg DKK1592
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45.2 is an alloantigen of CD45, expressed by Ly5.2 bearing mouse strains (e.g., A, AKR, BALB/c, CBA/Ca, CBA/J, C3H/He, C57BL, C57BR, C57L, C58, DBA/1, DBA/2, NZB, SWR, 129). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in the mouse that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
B10.S mouse thymocytes and splenocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The 104 antibody does not react with mouse cells expressing the CD45.1 alloantigen. Additional reported applications (for the relevant formats) include: immunoprecipitation4, in vivo and in vitro blocking of B cell responses1,2, and immunohistochemical staining of acetone-fixed frozen sections3. 

Application References
  1. Yakura H, et al. 1983. J. Exp. Med. 157:1077. (Block)
  2. Yakura H, et al. 1986. J. Immunol. 136:2729. (Block)
  3. Suzuki K, et al. 2000. Immunity 13:691. (IHC)
  4. Shen FW, et al. 1986. Immunogenetics 24:146. (IP)
  5. Baldwin TA and Hogquist KA. 2007. J. Immunol. 179:837.
  6. Pascal V, et al. 2007. J. Immunol. 179:1751.
  7. Burman AC, et al. 2007. Blood 110:1064.
  8. Kincaid EZ, et al. 2007. J. Immunol. 179:3187.
  9. Phan TG, et al. 2007. Nature Immunol. 8:992.
  10. Nakano-Yokomizo T, et al. 2011. J. Exp Med. 208:1661. PubMed
  11. Wen T, et al. 2013. PNAS. 110:6067. PubMed
  12. Kohlmeier JE, et al. 2008. Immunity. 29:101. (FC) PubMed
Product Citations
  1. Lee KM, et al. 2022. Cancer Immunol Res. 10:829. PubMed
  2. Li T, et al. 2022. J Leukoc Biol. 112:845. PubMed
  3. Song S, et al. 2023. Bioact Mater. 28:358. PubMed
  4. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  5. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  6. Wang Y, et al. 2021. Cancer Res. 81:174. PubMed
  7. Nozaki K, et al. 2022. Nature. 606:960. PubMed
  8. VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed
  9. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  10. Vijver SV, et al. 2023. Front Immunol. 13:1100730. PubMed
  11. Sun Y, et al. 2023. Cell Mol Life Sci. 80:63. PubMed
  12. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  13. Li X, et al. 2022. Cell. 185:1709. PubMed
  14. Charpentier JC, et al. 2020. Nat Commun. 11:180. PubMed
  15. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  16. Emal D, et al. 2016. J Am Soc Nephrol. 10.1681/ASN.2016030255. PubMed
  17. Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed
  18. Zhang LJ, et al. 2019. Immunity. 50:121. PubMed
  19. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  20. Yu K, et al. 2021. Cell Reports. 35(12):109273. PubMed
  21. Scalzo S, et al. 2022. Int J Nanomedicine. 17:2865. PubMed
  22. Turner JS et al. 2018. Cell reports. 25(6):1395-1403 . PubMed
  23. Stewart I et al. 2018. Immunity. 49(3):477-489 . PubMed
  24. Fu B et al. 2017. Immunity. 47(6):1100-1113 . PubMed
  25. Low MSY, et al. 2019. Cell Reports. 29(9):2634-2645.e5. PubMed
  26. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  27. Rothchild AC, et al. 2020. Bio Protoc. 10:00. PubMed
  28. Isoda T et al. 2017. Cell. 171(1):103-119 . PubMed
  29. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  30. Rodriguez-Ruiz M, et al. 2016. Cancer Res . 76: 5994 - 6005. PubMed
  31. Kleinholz CL, et al. 2021. Sci Rep. 11:15071. PubMed
  32. Yang F, et al. 2020. Cancer Res. 80:3677. PubMed
  33. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  34. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  35. Stivala S, et al. 2019. J Clin Invest. 130:1596. PubMed
  36. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  37. Ramos CV, et al. 2020. Cell Reports. 32(3):107910. PubMed
  38. Tian Y, et al. 2016. J Immunol. 196: 2153 - 2166. PubMed
  39. Yap JY, et al. 2018. Immunology. 154:522. PubMed
  40. Zhang K, et al. 2014. PLoS Pathog. 10:1004385. PubMed
  41. Venturutti L, et al. 2020. Cell. 182(2):297-316.e27. PubMed
  42. Chen Z et al. 2019. Immunity. 51(5):840-855 . PubMed
  43. Hulsmans M et al. 2017. Cell. 169(3):510-522 . PubMed
  44. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  45. Xu S, et al. 2021. Immunity. . PubMed
  46. Stotesbury C, et al. 2020. J Immunol. 204:1582. PubMed
  47. Kan X, et al. 2015. Cardiovasc Res. 10.1093/cvr/cvv255. PubMed
  48. Fraccarollo D, et al. 2021. eLife. 0.416666666666667. PubMed
  49. Olson GS, et al. 2021. Cell Reports. 35(9):109195. PubMed
  50. Tian Y, et al. 2016. J Immunol. 197: 1308 - 1321. PubMed
  51. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  52. Liu C et al. 2019. Immunity. 51(2):381-397 . PubMed
  53. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  54. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  55. Giampazolias E, et al. 2021. Cell. . PubMed
  56. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  57. MacKinnon A, et al. 2011. Am J Respir Crit Care Med. 185:537. PubMed
  58. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  59. Ulland T, et al. 2016. Nat Commun. 7:13180. PubMed
  60. Wang X, et al. 2016. J Immunol. 197(12):4750-4761. PubMed
  61. Chen Z, et al. 2021. Cell. 184(5):1262-1280.e22. PubMed
  62. Forero A, et al. 2020. Immunity. 51(3):451-464. PubMed
  63. Tang W, et al. 2021. Front Cell Dev Biol. 9:728057. PubMed
  64. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  65. Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed
  66. Cao H, et al. 2020. Front Pharmacol. 11:578943. PubMed
  67. Martins R, et al. 2016. Nat Immunol. 17:1361-1372. PubMed
  68. Ikeda T, et al. 2014. PLoS One. 9:115198. PubMed
  69. Gundra UM, et al. 2017. Nat Immunol. 1.195833333. PubMed
  70. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  71. Cabal-Hierro L, et al. 2020. Nat Commun. 11:1406. PubMed
  72. Lee KM, et al. 2022. Cancer Immunol Res. 10:829. PubMed
  73. Li T, et al. 2022. J Leukoc Biol. 112:845. PubMed
  74. Song S, et al. 2023. Bioact Mater. 28:358. PubMed
  75. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  76. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  77. Wang Y, et al. 2021. Cancer Res. 81:174. PubMed
  78. Nozaki K, et al. 2022. Nature. 606:960. PubMed
  79. VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed
  80. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  81. Vijver SV, et al. 2023. Front Immunol. 13:1100730. PubMed
  82. Sun Y, et al. 2023. Cell Mol Life Sci. 80:63. PubMed
  83. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  84. Li X, et al. 2022. Cell. 185:1709. PubMed
  85. Charpentier JC, et al. 2020. Nat Commun. 11:180. PubMed
  86. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  87. Emal D, et al. 2016. J Am Soc Nephrol. 10.1681/ASN.2016030255. PubMed
  88. Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed
  89. Zhang LJ, et al. 2019. Immunity. 50:121. PubMed
  90. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  91. Yu K, et al. 2021. Cell Reports. 35(12):109273. PubMed
  92. Scalzo S, et al. 2022. Int J Nanomedicine. 17:2865. PubMed
  93. Turner JS et al. 2018. Cell reports. 25(6):1395-1403 . PubMed
  94. Stewart I et al. 2018. Immunity. 49(3):477-489 . PubMed
  95. Fu B et al. 2017. Immunity. 47(6):1100-1113 . PubMed
  96. Low MSY, et al. 2019. Cell Reports. 29(9):2634-2645.e5. PubMed
  97. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  98. Rothchild AC, et al. 2020. Bio Protoc. 10:00. PubMed
  99. Isoda T et al. 2017. Cell. 171(1):103-119 . PubMed
  100. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  101. Rodriguez-Ruiz M, et al. 2016. Cancer Res . 76: 5994 - 6005. PubMed
  102. Kleinholz CL, et al. 2021. Sci Rep. 11:15071. PubMed
  103. Yang F, et al. 2020. Cancer Res. 80:3677. PubMed
  104. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  105. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  106. Stivala S, et al. 2019. J Clin Invest. 130:1596. PubMed
  107. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  108. Ramos CV, et al. 2020. Cell Reports. 32(3):107910. PubMed
  109. Tian Y, et al. 2016. J Immunol. 196: 2153 - 2166. PubMed
  110. Yap JY, et al. 2018. Immunology. 154:522. PubMed
  111. Zhang K, et al. 2014. PLoS Pathog. 10:1004385. PubMed
  112. Venturutti L, et al. 2020. Cell. 182(2):297-316.e27. PubMed
  113. Chen Z et al. 2019. Immunity. 51(5):840-855 . PubMed
  114. Hulsmans M et al. 2017. Cell. 169(3):510-522 . PubMed
  115. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  116. Xu S, et al. 2021. Immunity. . PubMed
  117. Stotesbury C, et al. 2020. J Immunol. 204:1582. PubMed
  118. Kan X, et al. 2015. Cardiovasc Res. 10.1093/cvr/cvv255. PubMed
  119. Fraccarollo D, et al. 2021. eLife. 0.416666666666667. PubMed
  120. Olson GS, et al. 2021. Cell Reports. 35(9):109195. PubMed
  121. Tian Y, et al. 2016. J Immunol. 197: 1308 - 1321. PubMed
  122. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  123. Liu C et al. 2019. Immunity. 51(2):381-397 . PubMed
  124. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  125. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  126. Giampazolias E, et al. 2021. Cell. . PubMed
  127. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  128. MacKinnon A, et al. 2011. Am J Respir Crit Care Med. 185:537. PubMed
  129. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  130. Ulland T, et al. 2016. Nat Commun. 7:13180. PubMed
  131. Wang X, et al. 2016. J Immunol. 197(12):4750-4761. PubMed
  132. Chen Z, et al. 2021. Cell. 184(5):1262-1280.e22. PubMed
  133. Forero A, et al. 2020. Immunity. 51(3):451-464. PubMed
  134. Tang W, et al. 2021. Front Cell Dev Biol. 9:728057. PubMed
  135. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  136. Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed
  137. Cao H, et al. 2020. Front Pharmacol. 11:578943. PubMed
  138. Martins R, et al. 2016. Nat Immunol. 17:1361-1372. PubMed
  139. Ikeda T, et al. 2014. PLoS One. 9:115198. PubMed
  140. Gundra UM, et al. 2017. Nat Immunol. 1.195833333. PubMed
  141. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  142. Cabal-Hierro L, et al. 2020. Nat Commun. 11:1406. PubMed
RRID
AB_893352 (BioLegend Cat. No. 109827)
AB_893350 (BioLegend Cat. No. 109828)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets of the CD45.2 strain of mice

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules
Antigen References

1. Suzuki K, et al. 2000. Immunity 13:691.

Gene ID
19264 View all products for this Gene ID
UniProt
View information about CD45.2 on UniProt.org

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Other Formats

View All CD45.2 Reagents Request Custom Conjugation
Description Clone Applications
PE/Dazzle™ 594 anti-mouse CD45.2 104 FC
Purified anti-mouse CD45.2 (Maxpar® Ready) 104 FC,CyTOF®
Brilliant Violet 711™ anti-mouse CD45.2 104 FC
Alexa Fluor® 594 anti-mouse CD45.2 104 IHC-F,SB
APC/Fire™ 750 anti-mouse CD45.2 104 FC
TotalSeq™-A0157 anti-mouse CD45.2 104 PG
TotalSeq™-B0157 anti-mouse CD45.2 104 PG
TotalSeq™-C0157 anti-mouse CD45.2 104 PG
Brilliant Violet 750™ anti-mouse CD45.2 104 FC
Spark Blue™ 550 anti-mouse CD45.2 104 FC
Spark NIR™ 685 anti-mouse CD45.2 104 FC
Biotin anti-mouse CD45.2 104 FC
FITC anti-mouse CD45.2 104 FC
PE anti-mouse CD45.2 104 FC
Purified anti-mouse CD45.2 104 FC,Block,IHC-F,IP
APC anti-mouse CD45.2 104 FC
Alexa Fluor® 488 anti-mouse CD45.2 104 FC
Alexa Fluor® 647 anti-mouse CD45.2 104 FC
Pacific Blue™ anti-mouse CD45.2 104 FC
Alexa Fluor® 700 anti-mouse CD45.2 104 FC
APC/Cyanine7 anti-mouse CD45.2 104 FC
PerCP/Cyanine5.5 anti-mouse CD45.2 104 FC
PerCP anti-mouse CD45.2 104 FC
PE/Cyanine7 anti-mouse CD45.2 104 FC
Brilliant Violet 421™ anti-mouse CD45.2 104 FC
Brilliant Violet 570™ anti-mouse CD45.2 104 FC
Brilliant Violet 510™ anti-mouse CD45.2 104 FC
Brilliant Violet 650™ anti-mouse CD45.2 104 FC
Brilliant Violet 785™ anti-mouse CD45.2 104 FC
Brilliant Violet 605™ anti-mouse CD45.2 104 FC
Spark UV™ 387 anti-mouse CD45.2 104 FC
Spark Blue™ 574 anti-mouse CD45.2 (Flexi-Fluor™) 104 FC
Spark Red™ 718 anti-mouse CD45.2 (Flexi-Fluor™) 104 FC
Spark YG™ 581 anti-mouse CD45.2 (Flexi-Fluor™) 104 FC
Spark YG™ 593 anti-mouse CD45.2 (Flexi-Fluor™) Antibody 104 FC
Go To Top Version: 2    Revision Date: 09/18/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account